Publications by authors named "Ana Jimenez-Diaz"
Article Synopsis
- * The study involved 182 patients who received a combined pneumococcal vaccination protocol and evaluated their immune response through a specific assay measuring antibody functionality.
- * Results indicated that patients on the drug etanercept had a better immune response to multiple pneumococcal serotypes, with about 50% of all participants developing functional antibodies post-vaccination, especially for the prevalent serotype 3.
Background: Influenza vaccine is recommended for patients with autoimmune inflammatory diseases (AIID) on biological therapy.
Objective: To evaluate whether serological response to Influenza vaccine obtained in patients on biological therapy is similar to that achieved in patients on synthetic disease-modifying anti-rheumatic drugs (DMARDs) and that obtained in healthy controls.
Methods: We designed a cohort study in which patients with AIID, 68 on biological therapy and 46 on synthetic DMARDs, as well as 48 healthy controls, were included and vaccinated during the 2015-2016 influenza season.
To evaluate the response to hepatitis B virus (HBV) vaccine in patients on biological therapy. Adults with autoimmune inflammatory diseases on biological therapy such as anti-TNFα, rituximab, tocilizumab, abatacept, or anakinra were included. Hepatitis B surface antibody (anti-HBs) was measured by ELISA before and after vaccination.
View Article and Find Full Text PDFObjective: To evaluate whether immunological response to influenza vaccination is impaired in patients who are receiving secukinumab.
Patients And Methods: Subjects suffering from psoriatic arthritis or ankylosing spondylitis who were receiving treatment with secukinumab and healthy volunteers were included.All participants received seasonal inactivated trivalent influenza vaccine recommended by the WHO in the 2017-2018 northern hemisphere influenza season, which contained an A/Michigan/45/2015 (H1N1)pdm09-like virus, an A/Hong Kong/4801/2014 (H3N2)-like virus and a B/Brisbane/60/2008-like virus.
Background And Objectives: Influenza vaccine is recommended for patients with autoimmune inflammatory rheumatic diseases who receive biological therapy. To evaluate if biological therapy impairs immunization after seasonal influenza vaccine.
Material And Methods: Patients with inflammatory arthopathies, psoriasis, inflammatory bowel disease or connective tissue diseases who were receiving or were going to initiate biological therapy were included and vaccinated during 2014-2015 influenza season.